NF-κB, a central proinflammatory regulator, gets activated by TNF receptor-associated factors (TRAFs). But He et al. (page 2413) now report that one TRAF family member (TRAF3) instead negatively regulates an alternative NF-κB activation pathway.
Controlling clots with Clk1
Platelets are critical blood cells involved in clotting. An early step in clot construction requires tissue factor (TF), but whether platelets make TF was unknown. New work by Schwertz et al. (page 2433) reveals that these nucleifree cells doproduce TF by cytoplasmic splicing and further identify the kinase Clk1 as a splicing activator.
After injury to a blood vessel, platelets are the first cells on the scene to plug the hole. Platelets get activated by attachment to exposed collagen (amongst other things), and promote a TF-dependent coagulation cascade on their cell membranes. This ultimately results in large-scale fibrin production and the assembly of a tough fibrin meshwork over the platelet plug. TF is released from the injured tissue, but whether platelets themselves express TF is a debated question.
Schwertz et al. found that activated human platelets contained TF mRNA. Resting platelets instead contained unspliced TF pre-mRNA. Activation, the team showed, induced splicing and subsequent translation of TF in as little as 5 min.
Cytoplasmic splicing was described for the first time by this group a year ago. The precise mechanism is unknown, but splicing factor SF2/ASF was identified in platelet cytoplasms. In nucleated cells, Clk1 activates SF2/ASF by phosphorylation. Interrupting this modification, the team now shows, prevents processing of TF pre-mRNA.
A number of conditions lead to increased blood clotting. In recent unpublished work, the team found that platelets isolated from septic patients, in whom thrombosis occurs, are more prone to clotting and contain increased levels of spliced TF mRNA. Clk1-controlled splicing might thus be a good target for anticoagulation treatments.
Curtailing infection
Certain crafty viruses can cause the host's immune system to suppress itself, and thereby establish persistent chronic infection. But IL-10 is known to exert a suppressive effect on cells of the immune system, including T cells and antigen-presenting cells, and elevated levels of IL-10 have been observed during persistent infection with hepatitis C virus, human immunodeficiency virus, and Epstein-Barr virus. Now, both teams have observed that mice lacking IL-10 are resistant to persistent infection with lymphocytic choriomeningitis virus (LCMV). They also show that normal mice infected with LCMV have increased IL-10 production and decreased numbers of viruskilling CD8 + T cells. Ejrnaes et al. show that treating LCMV-infected mice with antibody that blocks the IL-10 receptor restored these antiviral CD8
+ T cells and resulted in low or undetectable viral load, less weight loss and healthier coats. Importantly, the same reversal of symptoms and eradication of virus was achieved if treatment was administered later in infection.
Blocking the action of IL-10 might, therefore, be a potential therapy for human cases of persistent viral infection. Prolonged treatment with a potent stimulator of the immune system, however, might lead to undesirable auto immune conditions, explains Matthias von Herrath, who led the study published here. His team is thus looking into the use of shorter and lower dose IL-10 treatments in combination with vaccines against virus-specific antigens.
